Drugs / JNJ-64304500
JNJ-64304500
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04712006 | May → Aug 2021 | — | Janssen Research & Development, LLC | Withdrawn | No outcome recorded |
| Phase 1 | NCT04667052 | Jan → Jun 2021 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03002025 | Jan → Sep 2017 | — | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04740970 | Mar 2021 → Jun 2022 | alopecia areata | Janssen Research & Development, LLC | Withdrawn | No outcome recorded |
| Phase 2 | NCT04655807 | Mar 2021 → May 2023 | Crohn disease | Janssen Research & Development, LLC | Withdrawn | No outcome recorded |
| Phase 2 | NCT02877134 | Aug 2016 → Dec 2020 | Crohn disease | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01203631 | Feb 2011 → May 2013 | Crohn disease | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-64304500 | “Participants will receive a single subcutaneous dose of JNJ-64304500 reference formulation.” NCT04667052 ↗ |
| Known as | NNC 0142-0000-0002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01203631 ↗ |
| Known as | NNC0142-0002 | “Anti-NKG2D (NNC0142-0002) is an antagonising human immunoglobulin G4 monoclonal antibody that binds to natural killer group 2 member D (NKG2D) receptors” PMID 27489241 ↗ Aug 2016 |
| Known as | Tesnatilimab | “Tesnatilimab, a monoclonal antibody targeting NKG2D, was evaluated in Crohn's disease [CD] patients who had failed or were intolerant to biologic or conventional therapy.” PMID 36939629 ↗ Aug 2023 |
| Action | Inhibit | “Anti-NKG2D (NNC0142-0002) is an antagonising human immunoglobulin G4 monoclonal antibody that binds to natural killer group 2 member D (NKG2D) receptors” PMID 27489241 ↗ Aug 2016 |
| Modality | Monoclonal antibody | “Anti-NKG2D (NNC0142-0002) is an antagonising human immunoglobulin G4 monoclonal antibody” PMID 27489241 ↗ Aug 2016 |
| Route | Subcutaneous | “a single subcutaneous (SC) dose of 2 mg/kg anti-NKG2D” PMID 27489241 ↗ Aug 2016 |